EANS-News: AGENNIX AG / Agennix Hires Jill Porter as Senior Vice President of Pharmaceutical Development

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Personnel

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and
Houston, TX, June 22, 2011 - Agennix AG (Frankfurt Stock Exchange:
AGX) today announced the appointment of Jill Porter, Ph.D. as Senior
Vice President, Pharmaceutical Development, reporting to Dr. Rajesh
Malik, Chief Medical Officer. In this position, Dr. Porter is
leading all activities related to supply chain, global production and
CMC (chemistry, manufacturing and controls) for talactoferrin, an
oral immunotherapy being studied for the treatment of non-small cell
lung cancer and for severe sepsis.

Rajesh Malik, M.D., Chief Medical Officer, said, "I am very pleased
to welcome Dr. Porter to Agennix. She has extensive experience in
leading production and supply chain activities and developing
strategic plans in these areas for both development-stage and
marketed biologic products. Dr. Porter is an excellent addition to
our management team in an area of critical importance, as we prepare
for a possible regulatory filing for talactoferrin and a potential
commercial launch."

Dr. Porter has nearly twenty years of biopharmaceutical industry
experience. She has held senior executive positions with
responsibility for manufacturing and process development at Taligen
Therapeutics, Altus Pharmaceuticals and Alexion Pharmaceuticals,
where she worked immediately prior to joining Agennix. She worked
for many years in positions of increasing responsibility at
Hoffman-La Roche, including leading the Biopharmaceuticals
department, with responsibility for the clinical and commercial
manufacturing of two biologic drugs. Dr. Porter has experience in
clinical and commercial supply chain management, as well as with
regulatory filings and product approvals. She received a Ph.D. in
agricultural engineering from Purdue University and an MBA from
Columbia University.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral
immunotherapy that has demonstrated activity in randomized,
double-blind, placebo-controlled Phase II studies in non-small cell
lung cancer and in severe sepsis. Talactoferrin is currently in Phase
III clinical trials in non-small cell lung cancer, and Agennix is
also continuing the development of this program for the treatment of
severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and
a topical gel form of talactoferrin for diabetic foot ulcers.
Agennix's registered seat is in Heidelberg, Germany. The Company has
three sites of operation: Planegg/Munich, Germany; Princeton, New
Jersey and Houston, Texas. For additional information, please visit
the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. There can be no guarantee
that the Company will move talactoferrin forward in development for
severe sepsis in a timely manner, if at all. Even if the results
from our later stage trials with talactoferrin, including the ongoing
FORTIS-M trial in non-small cell lung cancer, are considered
positive, they may not be sufficient to gain marketing approval in
the United States or any other country, and the regulatory
authorities may require additional information, data and/or further
pre-clinical or clinical studies to support approval. In such event,
there can be no guarantee that the Company will have or be able to
obtain the financial resources to conduct any such additional studies
or that such studies will yield results sufficient for approval.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English